Alumni Capital Management
VC Fund
Miami, United States
Alumni Capital Management is an alternative investment management firm. The company takes a millennial approach to the public markets, offering a unique perspective on investment strategies. It provides financial services and impact investing, focusing on the public markets. The company also plays a role in the world of finance, specifically inInvestment Management. Alumni Capital Management has been involved in various financial transactions, such as helping Motorsport Games regain full compliance with Nasdaq Listing Rules and facilitating US Lighting Group's growth through a purchase agreement.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 85%
Last updated:
For AI agents: llms.txt
Industries Alumni Capital Management invests in
BiotechnologyHealth CareMedicalSoftwareEdTech
Stages Alumni Capital Management invests in
Post-IPO EquityPost-IPO Debt
Countries Alumni Capital Management invests in
CanadaFranceUnited StatesIsraelSweden
Investment Focus
Industry
- Biotechnology 5 (38%)
- Health Care 4 (31%)
- Medical 2 (15%)
- Software 2 (15%)
- EdTech 1 (8%)
Stage
- Post-IPO Equity 10 (77%)
- Post-IPO Debt 1 (8%)
Country
- Canada 2 (15%)
- France 2 (15%)
- United States 2 (15%)
- Israel 1 (8%)
- Sweden 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wyld Networks
|
Founded in 2016 with an objective of enabling affordable low power IoT connectivity using LEO Satellites. Wyld Connect leverages low power wireless technology and low earth orbiting satellites using LoRaWAN. Wyld enables affordable IoT connectivity across the globe in areas where there is no wireless coverage.Based in Cambridge UK and listed onthe NASDAQ FN exchange, Wyld Networks are an energetic, creative technology company with a pedigree in wireless electrical engineering.Experts in LPWAN, Wyld offers innovative hardware, software and data plans to deliver the best solution for IoT connectivity problems in any given environment. | $513.1K / Post-IPO Equity / Jun 30, 2026 | |
Scandinavian Enviro Systems
|
Scandinavian Enviro Systems AB was founded in 2001. At that time, the newly-established company was still working to verify and develop CFC technology, to refine its economies of scale, assure the quality of the end products, and to improve the pyrolysis process. From 2005 to 2010, the company built six pilot plants of varying sizes. The company’swork to further develop the technology resulted in an application for a second patent entitled “Plant for the recovery of carbon and hydrocarbon compounds through pyrolysis”, submitted in 2006 and granted in 2009. This patent is called EHD, which stands for “Enhanced Heat Distribution”. Production capacity has been steadily expanded from what began at 5 litres per batch in the first plant; today’s plant has a production capacity of around six metric tons per reactor. | $5.3M / Post-IPO Equity / May 22, 2026 | |
RedHill Biopharma
|
RedHill Biopharma is a pharmaceutical company focused primarily on acquisition and development of late clinical-stage new, improved and patented formulations of existing drugs, with preference to a 505(b)(2)* regulatory paths, as well as acquisition and developement of late clinical-stage, new and patented orphan drugs. | $10M / Post-IPO Equity / Apr 27, 2026 | |
Shape Robotics
|
Shape Robotics has developed Fable robot system, which is a modular robot system for use in teaching students from 2nd grade to university.Fable is a robotic construction system that makes it easy for anyone to create their own robots. Different types of modules can be snapped together in countless ways to create the robot's body, sensesand movements. Dependent on the user’s level of experience, the robot can be programmed using tools for either beginners or professionals. Fable makes it possible to use creative play to learn about technology and innovation - a solid foundation of knowledge. | $1.2M / Post-IPO Debt / Apr 14, 2026 | |
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $3.4M / Post-IPO Equity / Dec 26, 2025 | |
|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $4.3M / Post-IPO Equity / Sep 26, 2025 | |
ABL Diagnostics
|
ABL Diagnostics is a business that develops medical software and diagnostics. The group has concentrated on the development of software for collecting and processing medical databases, measuring care quality, diagnosing infectious diseases through genotyping, and providing decision support to doctors and nurses, virology and microbiologylaboratories, and researchers dealing with patients suffering from chronic and complex diseases. | Post-IPO Equity / Aug 05, 2025 | |
Brazil Potash
|
Brazil Potash aims to invest in a cleaner, sustainable future. Founded in 2009 by both Brazilian and foreign investors, the company’s foundations began with a singular goal to help achieve an independent and local output of potash in Brazil. Brazil Potash has since taken several years of exploratory drilling under proper legislation, complying withenvironmental studies, preparing and implementing environmental and social programs and consulting local indigenous populations to prepare for the next chapter in this company’s venture. Brazil Potash understands that potash is a key resource for farming. Potash makes soil arable, contributes to long-term farming of the same land plot, and is one of the most important exports for the agricultural sector. However, though Brazil may be one of the world’s largest and fastest-growing markets for potash, currently roughly 95% of its potash is imported from foreign countries.The company plans to begin extraction on its Autazes Potash Project, which is 120 km southeast of Manaus. Brazil Potash aims to make available up to 2,600 direct jobs during its installation phase and 1,300 during its operation phase, as well as 12 times that number in indirect positions. It also stands to connect the municipality to necessary infrastructure for quality of life, and grant the municipality increased tax revenues that can be reinvested into schools, water quality, roads and healthcare services. Brazil Potash has been recognized internationally for its plan to reduce greenhouse gas emissions caused by potash imports by upwards of 65%. Brazil Potash is led by executives who include CEO Matt Simpson, Brazil President Adriano Espeschit, Head of Finance, Davidson Aquino, geology specialists Gustavo Kiefer, Marketing Director Marcos Pedrini, Project Director Rafael Bloise and ESG Director Lúcio Rabelo.Brazil Potash’s technical headquarters is stationed in Autazes. Brazil Potash also includes a corporate office in Toronto, and its administrative branch is located in Manaus and Belo Horizonte, Brazil. | $54.5M / Post-IPO Equity / May 06, 2025 | |
Azitra
|
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory,is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. | $20M / Post-IPO Equity / Apr 24, 2025 | |
Oncolytics Biotech
|
Oncolytics Biotech focuses the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth anddifferentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company.Oncolytics Biotech was founded on 1988 and is based in Calgary, Alberta, Canada. | $20M / Post-IPO Equity / Apr 10, 2025 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
EdTech Investors
18,221 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Alumni Capital Management invest in?
Alumni Capital Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Post-IPO Debt stage. Most of the 13 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alumni Capital Management last invest?
The most recent investment recorded for Alumni Capital Management closed in Jun 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
